The specific functions and effects of dupilumab/dalbitux injection

Dupilumab (dupilumab) is an innovative treatment for immune-mediated diseases. It mainly helps regulate immune responses by inhibiting the IL-4 and IL-13 signaling pathways. As a human monoclonal IgG4 antibody, it inhibits the signaling of these cytokines by specifically binding to the IL-4Rα subunit of the IL-4 and IL-13 receptor complex, thereby effectively alleviating the symptoms of immune-related diseases.

Duplimumab effectively prevents the negative effects of these cytokines on the immune system by inhibiting theIL-4 signaling pathway and IL-13 signaling pathway. Specifically, dupilumab inhibits IL-4 signaling through type I receptors and simultaneously inhibits IL-4 and IL-13 signaling through type II receptors, thereby reducing immune system overreaction. Through this mechanism, dupilumab can significantly reduce inflammation, alleviate allergic reactions, and improve symptoms of related diseases, such as skin itching, acute asthma attacks, etc.

In the treatment of atopic dermatitis (AD), dupilumab has been shown to significantly improve skin symptoms, reduce inflammation, and improve patients' quality of life. Clinical data show that skin inflammation and itching symptoms are significantly improved in patients treated with dupilumab, and some patients can see significant symptom relief within a few weeks of treatment.

Dupilumab has also shown positive results in the treatment of conditions such as asthma and chronic sinusitis with nasal polyps. For patients with severe asthma, it can significantly reduce the frequency of exacerbations while improving lung function and reducing reliance on traditional inhaled medications. For patients with nasal polyps, dupilumab also showed good results, being able to significantly reduce the size of nasal polyps and relieve related symptoms such as nasal congestion and runny nose.

In general, dupilumab is an immunomodulatory drug with a wide range of indications. It improves the symptoms of a series of immune-related diseases mainly through its inhibitory effect onIL-4 and IL-13 signaling.

Keyword tags: dupilumab, Dupilumab, Dalbitux, immunomodulation, IL-4, IL-13, atopic dermatitis, asthma, nasal polyps, antibody treatment

Reference materials:https://www.dupixent.com/